Researchers have demonstrated that artificial intelligence can extract precise cancer biomarker information directly from routine tissue images, delivering results in minutes instead of weeks and without destroying tissue samples in the process. A multi-site clinical validation study published in Clinical Breast Cancer confirms that Panakeia's PANProfiler Breast software accurately identifies three critical molecular markers (ER, PR, and HER2) from brightfield images across multiple independent healthcare institutions, establishing a scalable foundation for AI-driven precision oncology.

How Does This AI Technology Actually Work?

The PANProfiler platform uses a biology-first approach, trained on petabytes of population-scale data to recognize molecular patterns invisible to the human eye in standard tissue images. Rather than requiring traditional "wet-lab" assays that consume tissue samples and take weeks to process, the software analyzes digital images of cells and tissues to determine biomarker status. The technology is built to profile thousands of biomarkers across DNA, RNA, proteins, and metabolites, supporting drug discovery, clinical development, and patient care decisions.

What makes this breakthrough significant is not just speed, but reliability. The validation study tested the software across different types of digital scanners and varying tissue preparation methods at multiple independent healthcare sites. The results showed consistent, diagnostic-grade performance regardless of these real-world variations, proving the technology works reliably in clinical practice.

Why Should Patients and Doctors Care About Faster Biomarker Testing?

For patients, the implications are profound. Traditional molecular testing can take weeks, during which patients and their care teams wait anxiously for results that determine which targeted therapies might work best. With AI-driven analysis, patients receive clarity on treatment options in minutes. The technology also preserves limited tissue samples, which is critical because some biopsies yield only small amounts of material. By eliminating the need for additional tissue destruction through wet-lab assays, clinicians can run multiple tests on the same sample if needed.

For oncologists, the AI identifies opportunities for more refined patient stratification by uncovering biological nuances that traditional testing might miss. This means more patients can be matched to the right targeted therapies, potentially improving treatment outcomes. The standalone diagnostic capability means the software functions as a complete replacement for traditional pathology testing, not merely as a screening aid.

What Evidence Supports This Technology's Reliability?

• Multi-Site Validation: The study demonstrated consistent performance across multiple independent healthcare institutions, proving the technology works reliably in real-world clinical settings rather than just laboratory conditions.
• Diagnostic-Grade Accuracy: PANProfiler Breast delivers high test-replacement rates with strong concordance to gold-standard pathology results, meaning it performs at the same level as established clinical testing methods.
• Scalability Across Cancer Types: The platform has already proven itself in colorectal cancer (PANProfiler Colorectal), published in npj Digital Medicine, matching gold-standard accuracy for MSI and MMR biomarkers, establishing a foundation for expansion to other cancer types.
• Regulatory Approval: PANProfiler Breast is UKCA-marked, a medical device designation indicating it meets regulatory standards for clinical use in the United Kingdom and European markets.

The colorectal cancer study, which preceded this breast cancer validation, proved the platform matches gold-standard accuracy for both MSI (DNA) and MMR (protein) biomarkers while operating robustly across multiple clinical sites and delivering results in significantly faster timeframes.

"The publication of this study is another important milestone in our journey to make the highest standard of precision medicine accessible to doctors and patients across the world. By proving that we can deliver diagnostic-grade biological insights from routine brightfield images, we are providing the essential tools needed to transform clinical decision-making and ensure patients receive personalized, life-saving therapies without delay," stated Pahini Pandya, Founder and Chief Executive Officer of Panakeia.

Pahini Pandya, Founder and Chief Executive Officer of Panakeia

What's Next for AI in Cancer Diagnosis?

Panakeia is moving beyond static biomarker detection toward uncovering the functional hallmarks of cancer. Preliminary results presented at the American Association for Cancer Research (AACR) 2026 conference suggest the technology is headed toward providing a complete biological blueprint of tumors, not just identifying individual markers. This deeper understanding could accelerate drug development and reduce failure rates in clinical trials by helping researchers and pharmaceutical companies identify more promising therapeutic targets.

The company is actively working with international regulatory bodies and industry partners to establish rigorous evidence standards for safe, patient-centric AI. Panakeia participates in the Friends of Cancer Research Digital PATH Project alongside the FDA and the UK MHRA's AI Airlock programme, helping define regulatory roadmaps to safely bring AI-driven diagnostic solutions to patients worldwide.

Two UKCA-marked clinical products derived from the PANProfiler platform are already deployed in hospitals, enabling faster and more accessible precision diagnostics today. As the technology expands to additional cancer types and biomarker classes, the potential to transform oncology practice grows substantially, offering clinicians and patients a faster, more accurate path to personalized treatment decisions.